Loading candles…
Alembic Pharmaceuticals Ltd. operates in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of generic pharmaceutical products and active pharmaceutical ingredients (APIs) globally. The company’s business segments include India Branded Business, International Generics, and APIs. It serves markets primarily in India and the United States. Alembic Pharmaceuticals maintains three research and development centers and five manufacturing facilities. The company has a legacy spanning over a century. No information is available regarding its incorporation year, founders, key management, subsidiaries, notable projects, or stock exchange listings.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period and financial year ended March 31, 2026 and dividend for the financial year ended March 31, 2026 | 15 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 5 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 and other business matters | 4 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters | 5 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 6 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.